Publication:
Chiral DOTA chelators as an improved platform for biomedical imaging and therapy applications

Thumbnail Image

Open/View Files

Date

2018

Journal Title

Journal ISSN

Volume Title

Publisher

Nature Publishing Group UK
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Dai, L., C. M. Jones, W. T. K. Chan, T. A. Pham, X. Ling, E. M. Gale, N. J. Rotile, et al. 2018. “Chiral DOTA chelators as an improved platform for biomedical imaging and therapy applications.” Nature Communications 9 (1): 857. doi:10.1038/s41467-018-03315-8. http://dx.doi.org/10.1038/s41467-018-03315-8.

Research Data

Abstract

Despite established clinical utilisation, there is an increasing need for safer, more inert gadolinium-based contrast agents, and for chelators that react rapidly with radiometals. Here we report the syntheses of a series of chiral DOTA chelators and their corresponding metal complexes and reveal properties that transcend the parent DOTA compound. We incorporated symmetrical chiral substituents around the tetraaza ring, imparting enhanced rigidity to the DOTA cavity, enabling control over the range of stereoisomers of the lanthanide complexes. The Gd chiral DOTA complexes are shown to be orders of magnitude more inert to Gd release than [GdDOTA]−. These compounds also exhibit very-fast water exchange rates in an optimal range for high field imaging. Radiolabeling studies with (Cu-64/Lu-177) also demonstrate faster labelling properties. These chiral DOTA chelators are alternative general platforms for the development of stable, high relaxivity contrast agents, and for radiometal complexes used for imaging and/or therapy.

Description

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Referenced By

Related Stories